Zhu Yong, Yue Jin, Liu Zheng-jian, Huang Jian, Bian Ting-song, Wang Jin-song, Zeng Qing-qi
Zhonghua Nan Ke Xue. 2015 Dec;21(12):1116-20.
To investigate the clinical effectiveness of sertraline hydrochloride combined with four-spot caress in the treatment of primary premature ejaculation (PE).
We randomly assigned 90 primary PE patients to three groups of equal number. The patients in group A (aged [28.1 ± 5.2] yr and with a disease course of [3.1 ± 1.9] yr) were treated with oral sertraline hydrochloride at 50 mg qd, those in B (aged [27.8 ± 4.1] yr and with a disease course of [3.2 ± 2.0] yr) by four-spot caressing (caressing the tongue, breasts, and vulva prior to intercourse), and those in C (aged [27.1 ± 4.7] yr and with a disease course of [3.1 ± 2.0] yr) by the combination of oral sertraline hydrochloride and four-spot caressing, all for 12 weeks. Before and after 4, 8, and 12 weeks of treatment, we obtained the intravaginal ejaculatory latency time (IELT) and Chinese Index of Sexual Function for Premature Ejaculation-5 (CIPE-5) scores and compared them among the three groups of patients.
The IELT was dramatically prolonged in groups A, B, and C after 4 weeks ([1.08 ± 0.29], [0.93 ± 0.28] and [1.21 ± 0.27] min), 8 weeks ([1.43 ± 0.30], [1.20 ± 0.33] and [1.72 ± 0.42] min) and 12 weeks of treatment ([2.12 ± 0.63], [1.90 ± 0.65] and [2.67 ± 0.82] min) as compared with the baseline ([0.63 ?0.14] , [0.60 ?0.14] and [0.62 ?0.11] min) (P < 0.05), even longer in group C than in A and B (P < 0.05). The CIPE-5 scores were markedly improved in groups A, B and C after 4 weeks ([15.17 ± 1.74], [14.57 ± 1.94] and [15.60 ± 1.63] min), 8 weeks ([17.13 ± 1.63], [16.37 ± 1.97] and [18.00 ± 1.05] min) and 12 weeks of intervention ([18.93 ± 1.57], [18.53 ± 1.67] and [20.00 ± 1.46] min ) as compared with the baseline ([12.57 ± 2.05], [13.20 ± 2.51] and [13.07 ± 2.01] min) (P < 0.05), even higher in group C than in A and B (P < 0.05).
Sertraline hydrochloride combined with four-spot caressing, with its definite efficacy and rare adverse reactions, deserves wide clinical application in the treatment of primary PE.
探讨盐酸舍曲林联合四点抚摸法治疗原发性早泄(PE)的临床疗效。
将90例原发性早泄患者随机分为人数相等的三组。A组患者(年龄[28.1±5.2]岁,病程[3.1±1.9]年)口服盐酸舍曲林,50mg/d;B组患者(年龄[27.8±4.1]岁,病程[3.2±2.0]年)采用四点抚摸法(性交前抚摸舌头、乳房和外阴);C组患者(年龄[27.1±4.7]岁,病程[3.1±2.0]年)采用口服盐酸舍曲林联合四点抚摸法,治疗均为12周。在治疗4、8和12周前后,分别记录阴道内射精潜伏期(IELT)及中国早泄性功能指数-5(CIPE-5)评分,并在三组患者间进行比较。
治疗4周后([1.08±0.29]、[0.93±0.28]和[1.21±0.27]分钟)、8周后([1.43±0.30]、[1.20±0.33]和[1.72±0.42]分钟)及12周后([2.12±0.63]、[1.90±0.65]和[2.67±0.82]分钟),A、B、C三组患者的IELT均较基线水平([0.63±0.14]、[0.60±0.14]和[0.62±0.11]分钟)显著延长(P<0.05),且C组延长程度大于A组和B组(P<0.05)。治疗4周后([15.17±1.74]、[14.57±1.94]和[15.60±1.63]分钟)、8周后([17.13±1.63]、[16.37±1.97]和[18.00±1.05]分钟)及12周干预后([18.93±1.57]、[18.53±1.67]和[20.00±1.46]分钟),A、B、C三组患者的CIPE-5评分均较基线水平([12.57±2.05]、[13.20±2.51]和[13.07±2.01]分钟)显著改善(P<0.05),且C组改善程度大于A组和B组(P<0.05)。
盐酸舍曲林联合四点抚摸法治疗原发性早泄疗效确切,不良反应少,值得临床广泛应用。